Objective: To determine the frequency of ICDs and other psychiatric complications in a serie of patients of the Movement Disorders Unit of our center, treated with LCIG.

Background: Impulse control disorders (ICDs) are a frequent complication in patients with Parkinson’s disease (PD) related to dopamine replacement therapy. Treatment with intestinal infusion of levodopa-carbidopa (LCIG) allows the reduction of doses or even withdrawing antiparkinsonian medication, providing a potential benefit in patients with ICDs. However the effectiveness of LCIG therapy on impulse control disorders is controversial.

Method: Observational study and analysis of demographic variables and characteristics related to the disease and treatment with LCIG
Statistical analysis was performed with parametric tests and descriptive statistics.

Results: Between 2009 and 2019, 31 patients have been treated with LCIG. 25.8% (7) presented TCI and 32% (10) other psychiatric complications (hallucinations and delirium). 9.7% presented both complications. 71% of the patients with TCI were male and the mean age was 69 ± 8 years. The average dose of levodopa was 1114 mg daily compared to 987.5 mg of those who did not experienced IDC (p <0.005). Of the 7 patients with TCI, 2 presented them for the first time with this therapy.

Conclusion: A significant proportion of patients treated with LCIG may experience ICDs, either recurrence of previous ICD or new onset

« Back to MDS Virtual Congress 2020

MDS Abstracts - https://www.mdsabstracts.org/abstract/impulse-control-disorders-and-other-psychiatric-complications-in-a-series-of-patients-treated-levodopa-carbidopa-instestinal-gel/